Alzheimer's disease (AD) is a progressive condition that causes the degeneration of nerve cells, leading to a decline in cognitive abilities and memory impairment, significantly affecting millions around the globe. The primary pathological feature of AD is the buildup of amyloid-β (Aβ) plaques in the brain, which has become a major target for therapeutic strategies. This thorough review examines the progress made in next-generation therapies that concentrate on monoclonal antibodies (mAbs) aimed at Aβ. We explore how these antibodies function, their effectiveness in clinical settings, and their safety profiles, specifically discussing notable mAbs, such as aducanumab, donanemab, lecanemab, etc. This review also addresses the difficulties related to Aβ- targeted treatments. Furthermore, it examines the advancing field of biomarker development and tailored medicine strategies designed to improve the accuracy of AD treatment. By integrating the latest findings from clinical trials and new research, this review offers an in-depth evaluation of the possibilities and challenges associated with mAbs in modifying the progression of AD. Future considerations regarding combination therapies and novel drug delivery methods are also examined, emphasizing the necessity for ongoing research to achieve significant advancements in managing AD. Through this review, we seek to provide clinicians, researchers, and policymakers with insights into the current landscape and future directions of Aβ-targeted therapies, promoting a deeper understanding of their role in addressing AD.
The detection of cancer remains a significant challenge due to limitations of current screening approaches, where usually several procedures and imprecise information are required. Liquid biopsy has emerged as an appealing method that makes it unnecessary to use invasive procedures. It depicts the biology of tumors at first sight based on circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes in the blood of the patient. This paper provides a review of the likelihood of the integration of liquid biopsy with medical imaging methods, such as MRI, CT, PET, and ultrasound, to enhance the accuracy of tumor identification. We expand on how liquid biopsy might improve healthcare imaging by defining tumor characterization more accurately and precisely, avoiding false positive and negative values, and providing genetic integration information that is often useful when interpreting imaging scans. Case examples are employed to demonstrate the seamless combination of liquid biopsy data with imaging outcomes, which can help expand the understanding of cancer pathophysiology and treatment sensitivity. However, artificial intelligence and machine learning should be used to support the execution of this supposed synergistically integrated strategy. The article also explains the problems concerning the integration of these two diagnostic methods and stresses the importance of standardizing the procedures and cooperation between the disciplines. This aggregation could result in earlier detection, improved monitoring, as well as individual approaches to cancer patients, hence leading to a significant increase in positive clinical outcomes.
Prostate cancer (PCa) is one of the most common cancers in men, distinguished by a multifaceted pathogenesis that involves substantial epigenetic modifications. This article emphasizes the critical role of chromatin remodeling in PCa advancement. Chromatin remodeling, a key epigenetic mechanism, influences gene expression by modulating the chromatin structure through the action of specialized complexes such as SWI/SNF, ISWI, CHD, & INO80, thereby regulating genes vital to tumor progression. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus databases for studies published between 2000 and 2025, focusing on chromatin remodeling, epigenetic alterations, and therapeutic strategies in PCa. The review discusses the major epigenetic changes observed in PCa, including DNA and RNA methylation, histone modifications, and non-coding RNA (ncRNA)-mediated chromatin remodeling. The evolving epigenetic landscape shaped by these alterations offers insights into novel therapeutic opportunities. The clinical relevance of targeting chromatin remodeling complexes is explored, alongside existing therapies and potential future interventions. This review also addresses challenges in studying chromatin remodeling and highlights emerging technologies that could enhance understanding of PCa epigenetics. This comprehensive exploration underscores the promise of chromatin remodeling as both a biomarker and a therapeutic target in PCa management.
Cytokine Release Syndrome (CRS) is a hyperinflammatory condition triggered by infections, immunotherapies, and systemic immune dysregulation. PANoptosis, a unique form of programmed inflammatory cell death that integrates pyroptosis, apoptosis, and necroptosis, has emerged as a key contributor to CRS pathogenesis. This review explores the mechanistic role of PANoptosis in CRS, with particular emphasis on immunotherapy-induced toxicity and viral infections such as SARS-CoV-2 and influenza. PANoptosis exacerbates cytokine storms through ZBP1, NLRP3, and CASP8-mediated pathways, creating a pathological feedback loop that intensifies inflammation and promotes multi-organ damage. Current evidence suggests that modulating PANoptotic pathways, including targeting TNF-α, IFN-γ, and inflammasome components, may mitigate cytokine-driven tissue injury. Despite growing interest, the therapeutic potential of PANoptosis remains underexplored. Advancing our understanding of PANoptosis and its interaction with cytokine signaling will be critical for developing effective interventions for CRS and improving outcomes in patients undergoing immunotherapy or battling severe infections.